Panic Disorder
📧 Sign up to get email alerts when something new happens for Panic Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approves a supplemental application from Aurobindo Pharma Limited to market a generic fluoxetine product.
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
FDA approved a supplemental application for fluoxetine submitted by Saptalis Pharmaceuticals, LLC.
-
FDA approval · 2017-01-04FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
The FDA approved a supplemental application for a generic Fluoxetine hydrochloride product from PAI Holdings dba PAI Pharma under ANDA 07601…
-
CLINICAL_TRIALS trial_result · 2016-12-30Clinical Trial Update: Org 25935 Versus Placebo as Augmentation to Cognitive-behavioral Therapy to Treat Panic Disorder (P05705) [Phase 2]
Phase 2 trial evaluating Org 25935 versus placebo as augmentation to cognitive-behavioral therapy for panic disorder; study terminated with …
-
FDA label_change · 2016-12-28FDA Approved: FLUOXETINE — Supplemental Application (Dr.Reddy's Laboratories Limited)
FDA approved a supplemental application for fluoxetine from Dr. Reddy's Laboratories Limited, indicating a labeling-related update to the ge…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-12-27FDA Approved: FLUOXETINE — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for fluoxetine hydrochloride from Lannett Company, Inc., resulting in approval of their generic fluo…
-
FDA approval · 2016-12-27FDA Approved: FLUOXETINE — Supplemental Application (PAI Holdings, LLC dba PAI Pharma)
FDA approved a supplemental application for fluoxetine hydrochloride from PAI Holdings, LLC dba PAI Pharma.
-
FDA approval · 2016-12-27FDA Approved: FLUOXETINE — Supplemental Application (Aurobindo Pharma Limited)
FDA granted a supplemental approval for a generic fluoxetine product from Aurobindo Pharma Limited under an ANDA.
-
FDA approval · 2016-12-27FDA Approved: FLUOXETINE — Supplemental Application (Saptalis Pharmaceuticals, LLC.)
The FDA approved a supplemental application for fluoxetine (generic) from Saptalis Pharmaceuticals, LLC, for continued marketing under the a…
-
FDA approval · 2016-12-23FDA Approved: SERTRALINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
The FDA approved a supplemental application for sertraline hydrochloride (generic) manufactured by Mylan Pharmaceuticals Inc.; this represen…
-
FDA approval · 2016-12-16FDA Approved: CLONAZEPAM — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for clonazepam submitted by Par Health USA, LLC.
-
FDA approval · 2016-12-16FDA Approved: CLONAZEPAM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for clonazepam from Teva Pharmaceuticals USA, Inc., marking regulatory approval of an updated approv…
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for alprazolam from Mylan Pharmaceuticals Inc., authorizing changes to the product under the NDA.
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental Abbreviated New Drug Application for alprazolam, a generic benzodiazepine manufactured by Par Health USA, LLC.
-
FDA approval · 2016-12-16FDA Approved: ALPRAZOLAM — Supplemental Application (Actavis Pharma, Inc.)
The FDA approved Actavis Pharma, Inc.'s supplemental application for alprazolam, resulting in a generic alprazolam product.
-
FDA approval · 2016-12-16FDA Approved: XANAX XR — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for Xanax XR (alprazolam) submitted by Viatris Specialty LLC. The action updates the labeling under …
-
FDA approval · 2016-11-25FDA Approved: VENLAFAXINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for a venlafaxine hydrochloride generic product from BluePoint Laboratories under ANDA077653. Th…
-
FDA approval · 2016-10-21FDA Approved: FLUOXETINE — Original Application (Torrent Pharmaceuticals Limited)
The FDA approved Torrent Pharmaceuticals Limited's original application for fluoxetine, authorizing the marketing of a generic fluoxetine pr…
-
CLINICAL_TRIALS research · 2016-09-27Clinical Trial Update: Initial Severity and Antidepressant Efficacy for Anxiety Disorders: an Individual Patient Data Meta-analysis
A clinical trial update presenting an individual patient data meta-analysis assessing baseline severity and antidepressant efficacy across s…
-
FDA approval · 2016-08-19FDA Approved: FLUOXETINE HYDROCHLORIDE — Original Application (Endo USA, Inc.)
FDA approves Endo USA, Inc.'s fluoxetine hydrochloride as an Original Application, providing a generic version of fluoxetine hydrochloride.
-
CLINICAL_TRIALS trial_result · 2016-08-02Clinical Trial Update: Long Term Treatment of Panic Disorder With Clonazepam or Paroxetine [Phase 4]
Phase 4 clinical trial comparing long-term treatment of panic disorder with clonazepam versus paroxetine has been completed, including parti…
-
FDA approval · 2016-08-01FDA Approved: PROZAC — Supplemental Application (Dista Products Company)
FDA approves a supplemental application for PROZAC (fluoxetine hydrochloride) submitted by Dista Products Company.
-
CLINICAL_TRIALS research · 2016-07-25Clinical Trial Update: A 10-Week, Open-Label, Flexible Dose Adaptive Study Evaluating the Efficacy of Vortioxetine in Subjects With Panic Disorder [Phase 4]
A Phase 4 open-label trial evaluating the efficacy of vortioxetine in subjects with panic disorder has completed.
-
FDA approval · 2016-07-18FDA Approved: CLONAZEPAM — Supplemental Application (Solco Healthcare LLC)
The FDA approved a supplemental application for clonazepam submitted by Solco Healthcare LLC.
-
FDA approval · 2016-07-18FDA Approved: CLONAZEPAM — Supplemental Application (Advagen Pharma Ltd)
The FDA approved a supplemental application for clonazepam submitted by Advagen Pharma Ltd.